Loading clinical trials...
Loading clinical trials...
NN5401-3594: A 26-week, Open-labelled, Two-arm, Parallel, Randomised Trial Comparing Efficacy and Safety of NN5401 Once Daily Plus Insulin Aspart vs. Basal-bolus Treatment With Insulin Detemir Plus Insulin Aspart in Subjects With Type 1 Diabetes / NN5401-3645: An Extension Trial Comparing Safety and Efficacy of NN5401 Plus Meal-time Insulin Aspart for the Remaining Meals With Insulin Detemir Plus Meal-time Insulin Aspart in Type 1 Diabetes (BOOST™: T1)
Conditions
Interventions
insulin degludec/insulin aspart
insulin detemir
+2 more
Locations
81
United States
Novo Nordisk Investigational Site
La Mesa, California, United States
Novo Nordisk Investigational Site
Lancaster, California, United States
Novo Nordisk Investigational Site
Mission Hills, California, United States
Novo Nordisk Investigational Site
North Hollywood, California, United States
Novo Nordisk Investigational Site
Salinas, California, United States
Novo Nordisk Investigational Site
Valencia, California, United States
Start Date
August 1, 2009
Primary Completion Date
May 1, 2010
Completion Date
May 1, 2010
Last Updated
March 20, 2017
NCT05398783
NCT07224321
NCT07395050
NCT01399385
NCT07340320
NCT07536516
Lead Sponsor
Novo Nordisk A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions